Thomas Gaj

8.8k total citations · 2 hit papers
48 papers, 6.3k citations indexed

About

Thomas Gaj is a scholar working on Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Thomas Gaj has authored 48 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 18 papers in Genetics and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Thomas Gaj's work include CRISPR and Genetic Engineering (40 papers), RNA Interference and Gene Delivery (11 papers) and Virus-based gene therapy research (10 papers). Thomas Gaj is often cited by papers focused on CRISPR and Genetic Engineering (40 papers), RNA Interference and Gene Delivery (11 papers) and Virus-based gene therapy research (10 papers). Thomas Gaj collaborates with scholars based in United States, China and Portugal. Thomas Gaj's co-authors include Carlos F. Barbas, Charles A. Gersbach, David V. Schaffer, Shannon J. Sirk, Jia Liu, Jing Guo, David S. Ojala, Andrew C. Mercer, M. Alejandra Zeballos C. and Prajit Limsirichai and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Thomas Gaj

48 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering

2013 2.7k citations Thomas Gaj, Charles A. Gersbach et al. profile →
A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons

2016 830 citations D. Gowanlock R. Tervo, Sarada Viswanathan et al. Neuron profile →

Peers

Countries citing papers authored by Thomas Gaj

Since Specialization

Citations

This map shows the geographic impact of Thomas Gaj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Gaj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Gaj more than expected).

Fields of papers citing papers by Thomas Gaj

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Gaj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Gaj. The network helps show where Thomas Gaj may publish in the future.

Co-authorship network of co-authors of Thomas Gaj

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Gaj. A scholar is included among the top collaborators of Thomas Gaj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Gaj. Thomas Gaj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SPLICER: a highly efficient base editing toolbox that enables in vivo therapeutic exon skipping 2024 ·Nature Communications ·(unknown), (unknown), Jackson Winter, (unknown), (unknown), (unknown), (unknown), Wendy S. Woods, (unknown), Michael Gapinske, M. Alejandra Zeballos C., (unknown), Sergei Maslov, Thomas Gaj, Pablo Pérez‐Piñera	3
2	Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins 2023 ·Nature Communications ·M. Alejandra Zeballos C., (unknown), Tyler Smith, Jackson E. Powell, (unknown), Sijia Zhang, Thomas Gaj	21
3	Delivering Base Editors In Vivo by Adeno-Associated Virus Vectors 2023 ·Methods in molecular biology ·(unknown), (unknown), Pablo Pérez‐Piñera, Thomas Gaj	2
4	CRISPR base editing of cis-regulatory elements enables the perturbation of neurodegeneration-linked genes 2022 ·Molecular Therapy ·(unknown), (unknown), Christian Saporito-Magriñá, (unknown), Ramya Krishnan, M. Alejandra Zeballos C., Jackson E. Powell, Lindsay V. Clark, Pablo Pérez‐Piñera, Thomas Gaj	15
5	Treatment of a Mouse Model of ALS by In Vivo Base Editing 2020 ·Molecular Therapy ·(unknown), Michael Gapinske, Alexandra K. Brooks, Wendy S. Woods, Jackson E. Powell, M. Alejandra Zeballos C., Jackson Winter, Pablo Pérez‐Piñera, Thomas Gaj	162
6	Innovations in CRISPR technology 2018 ·Current Opinion in Biotechnology ·Alexandra K. Brooks, Thomas Gaj	18
7	Defined and Scalable Differentiation of Human Oligodendrocyte Precursors from Pluripotent Stem Cells in a 3D Culture System 2017 ·Stem Cell Reports ·Gonçalo Rodrigues, Thomas Gaj, Maroof M. Adil, (unknown), Antara Rao, Franziska K. Lorbeer, Rishikesh U. Kulkarni, Maria Margarida Diogo, Joaquim M. S. Cabral, Evan W. Miller, Dirk Hockemeyer, David V. Schaffer	53
8	Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors 2016 ·PLoS ONE ·(unknown), Thomas Gaj, Mariana Santa‐Marta, Carlos F. Barbas, João Gonçalves	11
9	A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons breakdown → 2016 ·Neuron ·D. Gowanlock R. Tervo, (unknown), Sarada Viswanathan, Thomas Gaj, (unknown), Kimberly Ritola, Sarah Lindo, (unknown), Е. П. Кулешова, David S. Ojala, (unknown), Charles R. Gerfen, Jackie Schiller, Joshua T. Dudman, Adam W. Hantman, Loren L. Looger, David V. Schaffer, Alla Y. Karpova	830
10	Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications 2015 ·Molecular Therapy ·Thomas Gaj, (unknown), David V. Schaffer	90
11	CRISPR-mediated Activation of Latent HIV-1 Expression 2015 ·Molecular Therapy ·Prajit Limsirichai, Thomas Gaj, David V. Schaffer	88
12	Improved Cell-Penetrating Zinc-Finger Nuclease Proteins for Precision Genome Engineering 2015 ·Molecular Therapy — Nucleic Acids ·Jia Liu, Thomas Gaj, (unknown), Carlos F. Barbas	50
13	Protein Delivery Using Cys ₂ –His ₂ Zinc-Finger Domains 2014 ·ACS Chemical Biology ·Thomas Gaj, Jia Liu, (unknown), Shannon J. Sirk, Carlos F. Barbas	48
14	Comparing Genome Editing Technologies 2014 ·Genetic Engineering & Biotechnology News ·Charles A. Gersbach, Thomas Gaj, Carlos F. Barbas	1
15	Cell-Penetrating Peptide-Mediated Delivery of TALEN Proteins via Bioconjugation for Genome Engineering 2014 ·PLoS ONE ·Jia Liu, Thomas Gaj, James T Patterson, Shannon J. Sirk, Carlos F. Barbas	119
16	A comprehensive approach to zinc-finger recombinase customization enables genomic targeting in human cells 2013 ·Nucleic Acids Research ·Thomas Gaj, Andrew C. Mercer, Shannon J. Sirk, Heather Smith, Carlos F. Barbas	38
17	Chimeric TALE recombinases with programmable DNA sequence specificity 2012 ·Nucleic Acids Research ·Andrew C. Mercer, Thomas Gaj, Roberta Fuller, Carlos F. Barbas	99
18	Targeted gene knockout by direct delivery of zinc-finger nuclease proteins 2012 ·Nature Methods ·Thomas Gaj, Jing Guo, Yoshio Kato, Shannon J. Sirk, Carlos F. Barbas	232
19	Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase 2011 ·Nucleic Acids Research ·Charles A. Gersbach, Thomas Gaj, Russell M. Gordley, Andrew C. Mercer, Carlos F. Barbas	36
20	Directed evolution of recombinase specificity by split gene reassembly 2010 ·Nucleic Acids Research ·Charles A. Gersbach, Thomas Gaj, Russell M. Gordley, Carlos F. Barbas	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact